Chronic Myelogenous Leukemia in Childhood

Purpose of Review Chronic myelogenous leukemia (CML) is rare in children, requiring extrapolation from treatment of adults. In this review, we explore similarities and differences between adult and pediatric CML with a focus on therapeutic advances and emerging clinical questions. Recent Findings Pe...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology reports 2021-04, Vol.23 (4), p.40-40, Article 40
Main Authors: Smith, Stephanie M., Hijiya, Nobuko, Sakamoto, Kathleen M.
Format: Article
Language:English
Subjects:
Adolescent
Antineoplastic Agents - therapeutic use
Child
Childhood
Children
Chronic myeloid leukemia
Dasatinib
Hematopoietic Stem Cell Transplantation
Hematopoietic stem cells
Humans
Imatinib
Imatinib Mesylate - therapeutic use
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Medicine
Medicine & Public Health
Myeloid leukemia
Oncology
Pediatric Oncology (KL Davis
Pediatrics
Protein Kinase Inhibitors - therapeutic use
Protein-tyrosine kinase
Pyrimidines
Remission
Remission Induction
Section Editor
Stem cell transplantation
Topical Collection on Pediatric Oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of Review Chronic myelogenous leukemia (CML) is rare in children, requiring extrapolation from treatment of adults. In this review, we explore similarities and differences between adult and pediatric CML with a focus on therapeutic advances and emerging clinical questions. Recent Findings Pediatric CML is effectively treated with long-term targeted therapy using tyrosine kinase inhibitors (TKIs). Newly diagnosed pediatric patients in chronic phase can now be treated with imatinib, dasatinib, or nilotinib without allogeneic hematopoietic stem cell transplantation. While treatment-free remission is possible in adults in chronic phase with optimal response to therapy, data are currently insufficient to support stopping TKI in pediatrics outside of a clinical trial. Knowledge gaps remain regarding long-term and late effects of TKIs in pediatric CML. Summary Targeted therapy has markedly improved outcomes for pediatric CML, while raising a number of clinical questions, including the possibility of treatment-free remission and long-term health implications of prolonged TKI exposure at a young age.
ISSN:1523-3790
1534-6269
DOI:10.1007/s11912-021-01025-x